Regulatory scrutiny reinforces the need for accurate kratom testing and characterization

Santé Laboratories was invited to participate in this NutraIngredients-USA article reporting on current regulatory scrutiny of the kratom industry. The Food and Drug Administration (FDA) has collected input on kratom’s abuse potential, which it will forward to the World Health Organization to determine if there should be international restrictions placed on kratom and other substances.

Kratom manufacturers everywhere are currently feeling the weight of finding an appropriate laboratory for monitoring their supply chain. Santé Laboratories is the partner of choice for many kratom companies because of our innovative testing methodologies. Those testing methodologies include our seven-alkaloid panel for kratom, far exceeding competitors who typically can only visualize two of the major alkaloids.

As President of Santé Laboratories and CTO of Disruption Labs, Mike Sandoval told NutraIngredients-USA, Santé Laboratories has “successfully achieved chromatographic separation and identification of indole and oxindole alkaloids using Ultra-High Performance Liquid Chromatography instruments. Our analytical method was developed and validated for quantification of indole and oxindole alkaloids such as mitragynine, 7-hydroxymitragynine, paynantheine, speciogynine, speciociliatine, mitraphylline, isorhynchophylline and rhynchophylline.”

As the kratom industry continues to scale in the direction of food, dietary supplements and/or drugs, access to superior and scientifically valid testing services is of utmost importance for manufacturers, brands and retailers.